ATRA - アタラ・バイオセラピュ―ティクス (Atara Biotherapeutics Inc.) アタラ・バイオセラピュ―ティクス

 ATRAのチャート


 ATRAの企業情報

symbol ATRA
会社名 Atara Biotherapeutics Inc (アタラ・バイオセラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アタラ・バイオセラピューティックス(Atara Biotherapeutics Inc.)は臨床段階のバイオ医薬品会社である。同社は、重度の致命的な病気の患者の治療法の開発に注力している。同社は治療薬セグメントの開発および商業化事業を行っている。同社は同種異系または第三者由来の抗原特異的T細胞の開発に注力している。 T細胞は白血球の一種である。同社の製品候補であるATA129は、Epstein-Barrウイルス(EBV)の治療用のサードパティ派生Epstein-BarrウイルスCTLである。ATA188は、多発性硬化症の治療のために開発中である。サードパティ提供者のWT1-CTLであるATA520は、抗原Wilms Tumor 1(WT1)を発現する癌を標的とする。ATA520は第I相臨床試験中である。サードパティ由来のサイトメガロウイルスCTL(CMV-CTL)である同社のT細胞製品候補であるATA230は、難治性CMVの第II相臨床試験中である。   アタラ・バイオセラピュ―ティクスは米国のバイオ医薬品会社。筋消耗性疾患およびがんを対象に、未だ有効な治療方法がない医療ニ―ズに応える新薬の開発に注力する。新薬候補には末期の腎臓がん患者にみられる蛋白質・エネルギ―障害(PEW)治療用のPINTA 745、および卵巣がん治療用のSTM 434がある。   
本社所在地 611 Gateway Blvd. Suite 900 South San Francisco CA 94080 USA
代表者氏名 Isaac E. Ciechanover アイザック・E・チーチャナウバー
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 650-278-8930
設立年月日 41122
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 185人
url www.atarabio.com
nasdaq_url https://www.nasdaq.com/symbol/atra
adr_tso
EBITDA EBITDA(百万ドル) -160.94500
終値(lastsale) 37.61
時価総額(marketcap) 1705337179.33
時価総額 時価総額(百万ドル) 1674.051
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 1257.036
当期純利益 当期純利益(百万ドル) -158.73500
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Atara Biotherapeutics Inc revenues was not reported. Net loss increased 74% to $92.3M. Higher net loss reflects Other Research and Development increase of 75% to $55.5M (expense) Other General and Administrative increase from $11.4M to $24.5M (expense) Stock-based Compensation in R&D increase of 53% to $6.3M (expense).

 ATRAのテクニカル分析


 ATRAのニュース

   Mizuho Securities Stick to Their Buy Rating for Atara Biotherapeutics By Investing.com  2021/01/29 02:15:01 Investing.com
Mizuho Securities Stick to Their Buy Rating for Atara Biotherapeutics
   Atara Biotherapeutics to Present Data at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience  2021/01/19 21:14:00 Business Wire
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced the Company will present data in the form of six poster presentations at the Transplantation & Cellular Therapy (TCT) Meeting of the American Society for Transpla
   Atara Biotherapeutics Will Present Recent Advancements and Key Upcoming Milestones at the 39th Annual J.P. Morgan Healthcare Conference  2021/01/10 21:06:00 Business Wire
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA; the “Company”), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced President and Chief Executive Officer Pascal Touchon will present Atara’s 2020 progress and key upcoming milestones across the Company’s strategic prior
   Atara Biotherapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference  2021/01/06 13:30:00 Business Wire
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T- cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13 at 1:30 PM PST
   Mizuho Securities Stick to Their Buy Rating for Atara Biotherapeutics  2021/01/04 18:45:00 Investing.com
Mizuho Securities Stick to Their Buy Rating for Atara Biotherapeutics
   The Daily Biotech Pulse: Kazia Jumps On Data Readout, Clinical Hold On Cellectis' Blood Cancer Study Lifted  2020/11/18 12:29:45 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 17) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) ALX Oncology Holdings Inc (NASDAQ: ALXO ) (announced an oncology collaboration with Zymeworks Inc (NYSE: ZYME )) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Biodesix Inc (NASDAQ: BDSX ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN C4 Therapeutics Inc (NASDAQ: CCCC ) Champions Oncology Inc (NASDAQ: CSBR ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Edwards Lifesciences Corp (NYSE: EW ) Generation Bio Co (NASDAQ: GBIO ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Immunovant Inc (NASDAQ: IMVT ) Infinity Pharmaceuticals Inc. (NASDAQ: INFI ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Insmed Incorporated (NASDAQ: INSM ) Keros Therapeutics Inc (NASDAQ: KROS ) Kymera Therapeutics Inc (NASDAQ: KYMR ) LeMaitre Vascular Inc (NASDAQ: LMAT ) NeoGenomics, Inc. (NASDAQ: NEO ) Neuronetics Inc (NASDAQ: STIM ) Outset Medical Inc (NASDAQ: OM ) Prelude Therapeutics Inc (NASDAQ: PRL ) PTC Therapeutics, Inc.
   The Daily Biotech Pulse: Setback For Alkermes, Boston Scientific's Recall, ALX-Zymeworks Oncology Collaboration  2020/11/17 13:31:52 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 16) Aligos Therapeutics Inc (NASDAQ: ALGS ) (announced multiple presentations at the Liver Meeting) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Champions Oncology Inc (NASDAQ: CSBR ) CureVac BV (NASDAQ: CVAC )(announced a vaccine supply deal with the European Commission) Eidos Therapeutics Inc (NASDAQ: EIDX ) Generation Bio Co (NASDAQ: GBIO ) Immunovant Inc (NASDAQ: IMVT ) Infinity Pharmaceuticals Inc. (NASDAQ: INFI ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Kazia Therapeutics Ltd (NASDAQ: KZIA ) Keros Therapeutics Inc (NASDAQ: KROS ) Moderna Inc (NASDAQ: MRNA ) ( announced positive interim efficacy data for the Phase 3 study of its coronavirus vaccine candidate) Myokardia Inc (NASDAQ: MYOK ) Neuronetics Inc (NASDAQ: STIM ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Oncorus Inc (NASDAQ: ONCR ) Pacira Biosciences Inc (NASDAQ: PCRX ) Shockwave Medical Inc (NASDAQ: SWAV ) Spruce Biosciences Inc (NASDAQ: SPRB ) Summit Therapeutics Inc (NASDAQ: SMMT ) Syndax Pharmaceuticals Inc (NASDAQ: SNDX ) Tcr2 Therapeutics Inc (NASDAQ: TCRR ) TRACON Pharmaceuticals Inc (NASDAQ: TCON ) (announced regulatory filing for envafolimab in the indication of MSI-H/dMMR cancer, in China) Trinity Biotech plc (NASDAQ: TRIB ) United Therapeutics Corporation (NASDAQ: UTHR ) Veracyte Inc (NASDAQ: VCYT ) Vericel Corp (NASDAQ: VCEL ) Zai Lab Ltd – ADR (NASDAQ: ZLAB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Nov.
   Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences  2020/11/16 21:01:00 Business Wire
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today announced that Company management will participate at two upcoming virtual conferences. Stifel 2020 Virtual Healthcare Conference Wednesday, November 18, 2020 at 4:40 p.m. EST F
   Atara Biotherapeutics to boost ATA188 investment in multiple sclerosis treatment (NASDAQ:ATRA)  2020/11/15 15:43:20 Seeking Alpha
Atara Biotherapeutics (NASDAQ:ATRA) intends to present 15-month safety and efficacy data from all patients in the two highest dose cohorts of the Phase 1a
   Atara Biotherapeutics : to Present New Open-Label Extension Data, Including 15-Month Safety and Efficacy Data from Highest Dose Cohorts, in the Phase1a Study of ATA188 for Progressive Forms of Multiple Sclerosis at the ECF 28th Annual Meeting | MarketScreener  2020/11/15 15:01:01 MarketScreener
Long-term follow-up shows all patients who demonstrated sustained disability improvement maintained it at all subsequent timepoints 50 percent of patients in the two highest dose Cohorts … | November 15, 2020
   Atara Biotherapeutics Announces Second Quarter 2020 Financial Results and Operational Progress  2020/08/05 20:01:00 Business Wire
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease, today reported financial results for the second quarter ended June 30, 2020 and recent business highlights. “I am proud of the continued tremendous progress made by Atara’s team in del
   Atara Biotherapeutics to Announce Second Quarter 2020 Financial Results on Wednesday, August 5, 2020  2020/07/29 20:01:00 Business Wire
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases, including solid tumors, hematologic cancers and autoimmune disease, today announced the Company will release second quarter 2020 financial results after market close on Wednesday, August 5, 2020. Following the release, the Company will host a live conference call an
   Atara Biotherapeutics Announces its 2020 Annual Meeting of Stockholders Will Be Held on June 16, 2020 in Virtual Format  2020/06/05 20:15:00 Business Wire
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced that, due to public health and safety concerns related to the coronavirus (“COVID-19”) pandemic, recommendations and orders from federal, state and local authorities, and to support the health and well-being of its stockholders, employees, and others, it will host its 2020 Annual Meeting of Stockholders (“Annual Meeting”) as a virtual-only meeting that will be held via live audio webcast. Th
   Atara Biotherapeutics to Participate at Two Upcoming Conferences  2020/06/04 20:01:00 Business Wire
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease, today announced that Pascal Touchon, the Company’s President and Chief Executive Officer, will participate at two upcoming virtual conferences in June. Goldman Sachs 41st Annual Global Healthcare Con
   Atara Biotherapeutics Announces Pricing of $175.5 Million Public Offering  2020/05/27 05:16:00 Business Wire
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced the pricing of an underwritten public offering of 12,633,039 shares of its common stock at a price to the public of $11.32 per share and, to certain investors, pre-funde

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アタラ・バイオセラピュ―ティクス ATRA Atara Biotherapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)